Telormedix, a Swiss clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, has appointed Nicholas Ralphe Rogerson as chairman.
Rogerson has worked in the pharmaceutical industry for nearly 25 years in major companies, as well as in consulting and investment banking. He specialises in business development and advises pharma and biotech companies, investment banks and venture capitalists on issues such as partnering, M&A and strategic exits.
Following an early scientific career, Rogerson started in regulatory affairs and progressed to business development. He has been global head of pharmaceutical business development at Hoffmann-La Roche, head of corporate M&A for Novartis and md of Bear Stearns, leading its European Pharma M&A efforts.
Telormedix appoints new chairman
Nicholas Rogerson has taken the role
You may also like
Cleaning
Guardtech partner with Intense Pulsed Light innovators Biopulz to offer game-changing new cleanroom decontamination solution
New partnership will give Guardtech clients access to Biopulz’s mobile Eloane tower and integrated E-z̈o IPL decontamination system as part of their cleanroom installation projects
Analysis
Inspection readiness should be part of normal operations
For routine surveillance inspections, readiness cannot depend on receiving advance notice. Inspection readiness should be embedded in everyday operations, while recognising that preparation may need to become more intensive ahead of a known regulatory milestone
Pharmaceutical
T-Cypher Bio relocates to new Oxford facility to advance immune engager pipeline
The biotech firm has moved to a new facility at Abingdon Science Park, expanding its laboratory and tissue culture capabilities to support IND-enabling studies and the development of next-generation T-cell receptor-based therapeutics
Research & Development
TUM develops GNExT platform to identify potential Alzheimer’s drug candidates
The Technical University of Munich has developed a web-based tool that connects genome-wide association study data with biological networks, helping researchers identify disease mechanisms and potential drug repurposing opportunities